Significant differences exist with regard to time of discontinuation between different antipsychotic agents; for initial treatment, rapid onset/poor tolerability increases discontinuation, whilst for ...
KarXT (Karuna Therapeutics) met its primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia, the company has announced. KarXT is an oral coformulation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results